Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration

Fig. 2

Proportion of patients with SRF, IRF and sub-RPE. At baseline (prior to switch) (a) and at Month 12 (following switch) (b). IRF = intraretinal fluid; SRF = subretinal fluid; sub-RPE = sub-retinal pigment epithelium. Any treatment includes ranibizumab. *Twelve patients without SRF at baseline were found with SRF at least once over the follow-up and three of them switched from IVT-AFL to ranibizumab. Twenty-three patients without IRF at baseline were found with IRF at least once over the follow-up and one of them switched from IVT-AFL to ranibizumab. Thirteen patients without sub-RPE fluid at baseline were found with sub-RPE fluid at least once over the follow-up and two of them switched from IVT-AFL to ranibizumab

Back to article page
\